The 20 Most Disruptive Healthcare Solution providers The 20 Most Disruptive Healthcare Solution Provide | Page 30
Genpharm
A Foremost Pharmaceutical Organization
Offering Tailor-made and Comprehensive Solutions
G
enpharm is a leading regional pharmaceutical
market access and marketing company focused
mainly on niche therapeutics and diagnostics for
rare genetic diseases. The company has partnered with
multinational companies that have evidence-based and
innovative drugs looking to expand into the Middle East
and North Africa (MENA) region. The company operates
through an experienced and dedicated team of medical
science liaisons and key account managers. The company’s
partnerships are based on long-term regional commercial
agreements or in-licensing deals under the Genpharm
brand.
Outshining with its Diverse Services
Genpharm offers its expertise to achieve fast market access
for companies looking to expand into the Middle East
region. Being the exclusive partner for pharmaceutical
organizations, it offers every required service to its clients
at the highest standards which include regulatory, medical
and pharmacovigilance support, quality and logistics,
market access (pricing and reimbursement). It also
dedicates field staff for them to work closely with the key
stakeholders on disease awareness, patient support
programs, CME events, scientific meetings, advisory boards
and expert panels.
Karim Smaira
Founder & MP
”
Genpharm was established by the two influential Founders
& Managing Partners, Karim Smaira and Kamel
Ghammachi, whose leadership has been a consistent
presence in the MENA pharmaceutical sector for over forty
years. They both have successfully occupied several
industry roles and managed large multinational
pharmaceutical organizations in both regional and
international functions.
Kamel Ghammachi
Founder & MP
Our mission is to provide healthcare
organizations with innovative
therapeutic solutions in niche and
rare genetic disease areas, market
access strategies and sustainable
commercial solutions
”
|November 2018 | 28